President and Chief Executive Officer - IRICoR
Dr. Nadine Beauger is President and CEO of IRICoR, a Centre of Excellence in Commercialization and Research specializing in drug discovery in oncology and related areas, based at IRIC/University of Montreal. Under her leadership, Dr. Beauger has raised significant funding for her organization through federal and provincial government programs among other sources. IRICoR is rapidly expanding its project portfolio, providing academics with its tailor-made funding and support towards increasing their projects’ value and establishing strong partnerships with the private sector for innovative therapeutic solutions to reach the market faster. Before this appointment, Dr. Beauger was Vice-President – Scientific Liaison (intellectual property (IP), academia-industry relations) at that same organization that she joined in 2009. She was instrumental at building IRICoR’s project portfolio and related IP practice and strategy, which have led to successful licensing agreements and partnerships with industry. She had brought to IRICoR over 15 years of experience in technology assessment and transfer, venture capital, IP and project portfolio management, due diligence, and clinical and biotechnological research with thorough experience in both the private and the academic sectors. Dr. Beauger began her career as a Patent Consultant at Robic, a Montreal-based IP boutique, where she undertook drafting, prosecution and IP strategic management. She went on as Associate at VantagePoint Venture Partners (now VantagePoint Capital Partners), a leading California-headquartered venture capital firm with more than $4 billion under management. Just prior to joining IRICoR, Dr. Beauger was Business Development Manager at Paladin Labs Inc, a top specialty pharmaceutical company based in Montreal (now an Endo international company). She holds a Ph.D. in Biomedical Sciences (Hematology and Oncology), an M.Sc. in Cellular Biopathology from Université de Montréal and a B.Sc. in Anatomy from McGill University. She also holds an MBA degree from HEC Montréal (Excellence Studentship Award and Best Speaker Award). Dr. Beauger has been an invited speaker at a number of national and international events and is a Board member of CHU Ste-Justine Foundation, ExCellThera, one of IRICoR’s spin-off companies and a clinical-stage cell and molecular medicine company and Immune BioSolutions, a Sherbrooke-based innovative biotech specialized in antibody production.
See the program of this speaker